Trials / Completed
CompletedNCT02780115
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 40 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 ophthalmic solution | 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye. |
| DRUG | AGN-190584 ophthalmic solution | 1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye. |
| DRUG | AGN-199201 Vehicle | Vehicle to AGN-199201 |
| DRUG | AGN-190584 Vehicle | Vehicle to AGN-190584 |
Timeline
- Start date
- 2016-05-26
- Primary completion
- 2017-10-31
- Completion
- 2017-10-31
- First posted
- 2016-05-23
- Last updated
- 2020-12-22
- Results posted
- 2020-12-22
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02780115. Inclusion in this directory is not an endorsement.